• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    12/14/23 7:21:15 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care
    Get the next $PLSE alert in real time by email
    SC 13D/A 1 tm2332976d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 14)1

    Pulse Biosciences, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    74587B 10 1

    (CUSIP Number)

    ADAM W. FINERMAN, ESQ.

    BAKER HOSTETLER LLP

    45 Rockefeller Plaza

    New York, New York 10111

    (212) 589-4233

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 12, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            ROBERT W. DUGGAN  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            PF  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            U.S.A  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         37,975,319*  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              37,975,319*  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            37,975,319*  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            68.8%*  
      14   TYPE OF REPORTING PERSON  
             
            IN  

    * Represents (i) 37,975,319 Shares, including 147,506 Shares underlying certain options, (ii) 492,069 Shares held by Genius Inc, and (iii) 351,565 Shares held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof.

     

     

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            GENIUS INC.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         492,069  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              492,069  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            492,069  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0.9%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

     

     

                                           
      1   NAME OF REPORTING PERSON  
             
            BLAZON CORPORATION  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   SOURCE OF FUNDS  
             
            WC  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
             
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CALIFORNIA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         351,565  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
               
              351,565  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            351,565  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ☐
             
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            0.6%  
      14   TYPE OF REPORTING PERSON  
             
            CO  

     

     

     

    The following constitutes Amendment No. 14 to the Schedule 13D filed by the undersigned (the “Amendment No. 14”). This Amendment No. 14 amends the Schedule 13D as specifically set forth herein.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended and restated to read as follows:

     

    The aggregate purchase cost of the 36,984,179 Shares owned directly by Mr. Duggan is approximately $278,910,991, including brokerage commissions. Such Shares were acquired with personal funds. Mr. Duggan received his 147,506 stock options in connection with his service on the board of directors of the Issuer. The aggregate purchase cost of the 492,069 Shares owned by Genius Inc., which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $4,471,896, including brokerage commissions. Such Shares were acquired with working capital. The aggregate purchase cost of the 351,565 Shares owned by Blazon Corporation, which Mr. Duggan is the majority shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $3,248,715, including brokerage commissions. Such Shares were acquired with working capital.

     

    Item 5.

     

    Interest in Securities of the Issuer.

    Items 5(a)-(c) are hereby amended to read as follows:

     

    The aggregate percentage of Shares reported owned by each person named herein is based upon 55,080,527 Shares outstanding as of November 15, 2023, as reported in the Company’s definitive Proxy Statement filed with the SEC on November 27, 2023.

     

      A. Genius Inc.
         
      a) As of the close of business on December 12, 2023, Genius Inc. beneficially owned 492,069 Shares.
             
            Percentage: Approximately 0.9%

     

      b) 1. Sole power to vote or direct vote: 492,069
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 492,069
         
        4. Shared power to dispose or direct the disposition: 0

      

      c) Genius Inc. has not entered into any transactions in the Shares during the past sixty days.
         
      B. Mr. Duggan
         
      a)

    As of the close of business on December 12, 2023, Mr. Duggan directly owned 37,975,319 Shares, including 147,506 Shares underlying certain options exercisable within sixty days hereof. As the sole shareholder of Genius Inc., Mr. Duggan may be deemed the beneficial owner of the 492,069 Shares owned by Genius Inc. As the majority shareholder of Blazon Corporation, Mr. Duggan may be deemed the beneficial owner of the 351,565 Shares owned by Blazon Corporation

             
            Percentage: Approximately 68.8%

     

      b) 1. Sole power to vote or direct vote: 37,975,319
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 37,975,319
         
        4. Shared power to dispose or direct the disposition: 0

     

      c)

    The transactions in the Shares by Mr. Duggan during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

     

     

     

     

      C.

    Blazon Corporation

         
      a)

    As of the close of business on December 12, 2023, Blazon Corporation beneficially owned 351,565 Shares.

             
           

    Percentage: Approximately 0.6%

     

      b) 1. Sole power to vote or direct vote: 351,565
         
        2. Shared power to vote or direct vote: 0
         
        3. Sole power to dispose or direct the disposition: 351,565
         
        4. Shared power to dispose or direct the disposition: 0

     

      c)

    The transactions in the Shares by Blazon Corporation during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

     

    Transactions in the Common Stock During the Past Sixty Days
    Reporting Person Type of Security   Securities
    Purchased / (Sold)
        Price Per
    Share($)
        Date of
    Purchase / Sale
    Mr. Duggan Common Stock     17,999       9.15     12/12/2023
    Mr. Duggan Common Stock     90,118       9.36     12/11/2023
    Mr. Duggan Common Stock     116,656       9.54     12/8/2023
    Mr. Duggan Common Stock     74,852       9.19     12/7/2023
    Mr. Duggan Common Stock     82,813       9.06     12/6/2023
    Mr. Duggan Common Stock     9,933*       5.95     12/6/2023
    Blazon Corporation Common Stock     66,021       9.34     12/5/2023
    Mr. Duggan Common Stock     20,000*       10.66     12/4/2023
    Mr. Duggan Common Stock     20,347*       10.66     12/4/2023
    Blazon Corporation Common Stock     27,000       10.38     12/4/2023
    Blazon Corporation Common Stock     45,600       9.07     12/1/2023
    Blazon Corporation Common Stock     152,944       9.06     11/30/2023
    Blazon Corporation Common Stock     60,000       9.21     11/29/2023
    Mr. Duggan Common Stock     1,667 *     5.95     11/29/2023
    Mr. Duggan Common Stock     158,600       9.44     11/29/2023
    Mr. Duggan Common Stock     124,397       8.98     11/28/2023
    Mr. Duggan Common Stock     241       6.10     11/17/2023
    Mr. Duggan Common Stock     10,000       6.09     11/17/2023
    Mr. Duggan Common Stock     10,000       6.11     11/17/2023
    Mr. Duggan Common Stock     13,265 *     5.95     11/7/2023

     

    *Purchased pursuant to the exercise of stock options.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: December 14, 2023

     

      GENIUS INC.
       
      By:

    /s/ Martin Bittner

        Name: Martin Bittner
        Title: Chief Operating Officer
           
      BLAZON CORPORATION
           
      By: /s/ Robert W. Duggan
        Name: Robert W. Duggan
        Title: Authorized Signatory

     

     

     

    /s/ Robert W. Duggan

      Robert W. Duggan

     

     

     

    Get the next $PLSE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLSE

    DatePrice TargetRatingAnalyst
    7/7/2025$22.00Outperform
    Oppenheimer
    2/10/2022$43.00 → $20.00Buy
    HC Wainwright & Co.
    11/16/2021$46.00 → $43.00Buy
    HC Wainwright & Co.
    7/27/2021$28.00Overweight
    Stephens & Co.
    More analyst ratings

    $PLSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/17/24 8:02:46 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/17/24 6:05:11 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    12/13/24 7:30:48 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    SEC Filings

    View All

    SEC Form PRE 14A filed by Pulse Biosciences Inc

    PRE 14A - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/18/25 5:20:46 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Pulse Biosciences Inc

    10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/12/25 4:17:32 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    8/12/25 4:10:52 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Pulse Biosciences with a new price target

    Oppenheimer initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $22.00

    7/7/25 8:02:36 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $20.00 from $43.00 previously

    2/10/22 6:14:40 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Pulse Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $43.00 from $46.00 previously

    11/16/21 9:11:22 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PLSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablat

    8/12/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 am ET. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company's investor website at http://investors.pulsebiosciences.com/. About Pulse Biosciences® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intenti

    8/1/25 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About

    7/29/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Weber Steven

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    7/16/25 6:26:07 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Weber Steven

    3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    7/16/25 6:21:57 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Uecker Darrin sold $485,700 worth of shares (30,000 units at $16.19), decreasing direct ownership by 20% to 122,872 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    6/16/25 8:23:49 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

    Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025. "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecon

    2/4/25 8:00:00 AM ET
    $AXTA
    $PLSE
    $TFX
    Paints/Coatings
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

    Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter. "I am inspired by the potential of nano-PFA and the unique catheter

    10/30/24 4:02:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

    Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed Co-Chairman of the Board alongside Co-Chairman Robert W. Duggan, serving as an independent director. "We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical tech

    8/12/24 4:01:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Pulse Biosciences Inc

    SC 13D/A - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

    7/8/24 3:30:25 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

    12/14/23 7:21:15 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Pulse Biosciences Inc (Amendment)

    SC 13D/A - Pulse Biosciences, Inc. (0001625101) (Subject)

    12/4/23 5:18:06 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $PLSE
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablat

    8/12/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available on the Pulse Biosciences Investors website at http://investors.pulsebiosciences.com/. About

    7/29/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

    5/8/25 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care